Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GSK364735
GSK364735 · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| GSK364735 | DRUG | - |
| GSK364735 oral solution and oral tablets | DRUG | - |
Inclusion criteria: * Documented HIV-1 infection with screening viral load between 5000 and 300,000 copies/mL. * Baseline CD4 cell count greater than 100. * Females must be of non-childbearing potential * Not have received antiretroviral therapy in the 12 weeks prior to first dose. Exclusion crite...
GSK364735 is an investigational small molecule developed by GSK plc for the treatment of HIV infection, including HIV-1. It was studied as an oral therapy in both solution and tablet formulations. It is not an approved medicine and remains in clinical development.
GSK364735 was studied for the treatment of HIV infection, including HIV-1 infection, in adults. Clinical testing included a monotherapy study in integrase naive HIV-1 infected adults and a formulation and food effect study in healthy subjects. It is investigational and has not been approved for any use.
GSK364735 is developed by GSK plc, which trades under the ticker GSK. The company sponsored the clinical studies of the compound, including a Phase 2 monotherapy trial in HIV-1 infected adults and a Phase 1 formulation and food effect study in healthy subjects.
GSK364735 is in clinical development. The program includes a completed Phase 1 study of formulations and food effect in healthy subjects and a completed Phase 2 monotherapy study in integrase naive HIV-1 infected adults. It is investigational and has not been approved by the FDA.
GSK364735 has been evaluated in two completed trials: NCT00398125, a Phase 2 monotherapy versus placebo study over 10 days in integrase naive HIV-1 infected adults, and NCT00386347, a Phase 1 study evaluating formulations and food effect in healthy subjects. Both were conducted in the United States.